DALLAS, Oct. 30, 2023 /PRNewswire/ -- SWK Holdings Corporation (NASDAQ: SWKH) ('SWK' or the 'Company') today announced that B. Riley Securities has exercised its option to purchase $2,968,750 in additional unsecured Senior notes (the 'Notes') from its previously announced registered underwritten public offering (the 'Offering') of $30.0 million in aggregate principal amount of 9.00% Senior notes due 2027.

达拉斯，2023年10月30日/PRNewswire/-SWK Holdings Corporation（纳斯达克股票代码：SWKH）（'SWK'或'公司'）今天宣布B。莱利证券行使其选择权，从先前宣布的注册承保公开发行（'发行'）中购买额外无担保高级债券（'债券'）2968750美元，总额为3000万美元，截至2027年的9.00%高级债券。

The total net proceeds are now approximately $31.9 million (after deducting underwriting discounts and commissions, but before other fees and estimated expenses). .

净收益总额现在约为3190万美元（扣除承保折扣和佣金后，但在其他费用和估计费用之前）。 .

The Notes will mature on January 31, 2027, unless earlier redeemed, and will bear interest at a rate of 9.00% per annum, payable quarterly in arrears on March 31, June 30, September 30 and December 31 of each year and at maturity, commencing on December 31, 2023.

债券将于2027年1月31日到期，除非提前赎回，并将以每年9.00%的利率承担利息，每年3月31日，6月30日，9月30日和12月31日以及到期日，从2023年12月31日开始。

SWK intends to use the net proceeds from the Offering for general corporate purposes, including funding future acquisitions and investments, repaying indebtedness, making capital expenditures and funding working capital. The Notes were issued in minimum denominations of $25.00 and integral multiples of $25.00 in excess thereof.

SWK打算将该产品的净收益用于一般公司目的，包括为未来的收购和投资提供资金，偿还债务，进行资本支出和为营运资本提供资金。笔记以25.00美元的最低面额发行，超过25.00美元的整数倍数发行。

SWK and the Notes have been rated BBB- by Egan-Jones Ratings Company, an independent rating agency..

SWK和笔记已被独立评级机构Egan Jones评级公司评为BBB。。

The Notes are listed on the Nasdaq Global Market ('Nasdaq') under the symbol 'SWKHL'.

笔记在纳斯达克全球市场（'纳斯达克'）以符号'SWKHL'列出。

B. Riley Securities, Inc., Ladenburg Thalmann & Co. Inc. and William Blair & Company, L.L.C. acted as joint book-running managers for the Offering. InspereX LLC and Maxim Group LLC acted as co-managers for the Offering.

B、 Riley Securities，Inc.，Ladenburg Thalmann＆Co。Inc.和William Blair＆Company，L.L.C。担任该产品的联合经理。InspereX LLC和Maxim Group LLC担任该产品的共同经理。

This press release does not constitute an offer to sell or a solicitation of an offer to buy the securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

本新闻稿不构成出售或征求购买本文所述证券的报价，也不构成在任何州或其他司法管辖区出售这些证券，在根据任何此类管辖区的证券法注册或鉴定之前，此类报价，征求或销售将是非法的。

The Notes may only be offered and sold under SWK's registration statement on Form S-1 (including a prospectus), as amended and as may be supplemented by any free writing prospectus that the Company may file with the Securities and Exchange Commission ('SEC'), which has been filed with the SEC and declared effective on September 28, 2023.

该笔记只能根据SWK关于s-1表格（包括IPO）的注册声明提供和销售，经修订，并可辅以本公司可向证券交易委员会提交的任何自由书面IPO（'SEC'），已提交证券交易委员会，并于2023年9月28日宣布生效。

Copies of the registration statement may be obtained on the SEC's website at www.sec.gov or by contacting B. Riley Securities, Inc. by phone at (703) 312-9580 or by emailing [email protected]..

注册声明的副本可以在SEC的网站www.SEC.gov上获得，也可以通过电话（703）312-9580或通过电子邮件[受电子邮件保护]与B.Riley证券公司联系。。

About SWK Holdings CorporationSWK Holdings Corporation is a life science focused specialty finance company partnering with small- and mid-sized commercial-stage healthcare companies. SWK provides non-dilutive financing to fuel the development and commercialization of lifesaving and life-enhancing medical technologies and products.

关于SWK Holdings Corporation SWK Holdings Corporation是一家以生命科学为重点的专业金融公司，与中小型商业阶段医疗保健公司合作。SWK提供非稀释融资，促进救生和提高生命的医疗技术和产品的开发和商业化。

SWK's unique financing structures provide flexible financing solutions at an attractive cost of capital to create long-term value for all SWK stakeholders. SWK's solutions include structured debt, traditional royalty monetization, synthetic royalty transactions, and asset purchases typically ranging in size from $5.0 million to $25.0 million.

SWK独特的融资结构以吸引人的资本成本提供灵活的融资解决方案，为所有SWK利益相关者创造长期价值。SWK的解决方案包括结构化债务，传统版税货币化，合成版税交易和资产购买，通常规模从500万美元到2500万美元不等。

SWK also owns Enteris BioPharma, a clinical development and manufacturing organization providing development services to pharmaceutical partners as well as innovative formulation solutions built around its proprietary oral drug delivery technologies, the Peptelligence® platform..

SWK还拥有Enteris BioPharma，这是一家临床开发和制造组织，为制药合作伙伴提供开发服务，以及围绕其专有口服给药技术Peptelligence®平台构建的创新配方解决方案。。

Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements including words such as 'believes,' 'expects,' 'anticipates,' 'intends,' 'estimates,' 'plan,' 'will,' 'may,' 'look forward,' 'intend,' 'guidance,' 'future' or similar expressions are forward-looking statements.

前瞻性声明本新闻稿包含1995年“私人证券诉讼改革法”含义内的前瞻性声明。包括“相信”，“期望”，“预期”，“意图”，“估计”，“计划”，“将会”，“可能”，“展望”，“打算”，“指导”，“未来”或类似的表达是前瞻性的陈述。

Because these statements reflect SWK's current views, expectations and beliefs concerning future events, these forward-looking statements involve risks and uncertainties. Investors should note that many factors, as more fully described under the caption 'Risk Factors' and elsewhere in SWK's Form 10-K, Form 10-Q and Form 8-K filings with the Securities and Exchange Commission and as otherwise enumerated herein, could affect the Company's future financial results and could cause actual results to differ materially from those expressed in such forward-looking statements.

由于这些陈述反映了SWK对未来事件的当前观点，期望和信念，因此这些前瞻性陈述涉及风险和不确定性。投资者应该注意，许多因素，如“风险因素”标题中更全面描述的以及SWK表格10-K，表格10-Q和表格8-K与证券交易委员会提交的文件以及此处列举的其他内容，可能会影响公司未来的财务成果，并可能导致实际结果与此类前瞻性声明中表达的结果大不相同。

The forward-looking statements in this press release are qualified by these risk factors. These are factors that, individually or in the aggregate, could cause the Company's actual results to differ materially from expected and historical results. You should not place undue reliance on any forward-looking statements, which speak only as of the date they are made.

本新闻稿中的前瞻性声明受这些风险因素的限制。这些因素可能会导致公司的实际结果与预期和历史结果大不相同。您不应过分依赖任何前瞻性陈述，这些陈述仅在其作出之日起发言。

We assume no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise..

我们不承担公开更新任何前瞻性声明的义务，无论是由于新信息，未来发展还是其他原因。。

SOURCE SWK Holdings Corporation

SOURCE SWK Holdings Corporation